Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 2
2011 2
2012 2
2013 5
2014 8
2015 3
2016 9
2017 6
2018 8
2019 6
2020 14
2021 8
2022 12
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

84 results
Results by year
Filters applied: . Clear all
Page 1
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Among authors: moua t. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. Among authors: moua t. Eur Respir J. 2022 Mar 17;59(3):2004538. doi: 10.1183/13993003.04538-2020. Print 2022 Mar. Eur Respir J. 2022. PMID: 34475231 Free PMC article. Clinical Trial.
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.
Lee AS, Scofield RH, Hammitt KM, Gupta N, Thomas DE, Moua T, Ussavarungsi K, St Clair EW, Meehan R, Dunleavy K, Makara M, Carsons SE, Carteron NL; Consensus Expert Panel (CEP) Members. Lee AS, et al. Among authors: moua t. Chest. 2021 Feb;159(2):683-698. doi: 10.1016/j.chest.2020.10.011. Epub 2020 Oct 16. Chest. 2021. PMID: 33075377 Free PMC article.
Response.
Petnak T, Moua T. Petnak T, et al. Among authors: moua t. Chest. 2022 May;161(5):e331-e332. doi: 10.1016/j.chest.2021.12.661. Chest. 2022. PMID: 35526913 No abstract available.
Amyloid in the Lung.
Baqir M, Roden AC, Moua T. Baqir M, et al. Among authors: moua t. Semin Respir Crit Care Med. 2020 Apr;41(2):299-310. doi: 10.1055/s-0040-1708059. Epub 2020 Apr 12. Semin Respir Crit Care Med. 2020. PMID: 32279300 Review.
Late Complications of COVID-19.
Roden AC, Boland JM, Johnson TF, Aubry MC, Lo YC, Butt YM, Maleszewski JJ, Larsen BT, Tazelaar HD, Khoor A, Smith ML, Moua T, Jenkins SM, Moyer AM, Yi ES, Bois MC. Roden AC, et al. Among authors: moua t. Arch Pathol Lab Med. 2022 Jul 1;146(7):791-804. doi: 10.5858/arpa.2021-0519-SA. Arch Pathol Lab Med. 2022. PMID: 35319744 Free article.
A Bodybuilder with Dyspnea and Hypercalcemia.
Colbenson GA, Dempsey TM, Cecchini MJ, Aubry MC, Moua T, Ryu JH. Colbenson GA, et al. Among authors: moua t. Am J Med. 2021 Jun;134(6):e363-e365. doi: 10.1016/j.amjmed.2020.10.043. Epub 2020 Dec 11. Am J Med. 2021. PMID: 33316251 No abstract available.
Response.
Moua T, Levin DL, Ryu JH. Moua T, et al. Chest. 2013 Jul;144(1):362. doi: 10.1378/chest.13-0942. Chest. 2013. PMID: 23880695 No abstract available.
Idiopathic pulmonary fibrosis: evolving concepts.
Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP, Limper AH. Ryu JH, et al. Among authors: moua t. Mayo Clin Proc. 2014 Aug;89(8):1130-42. doi: 10.1016/j.mayocp.2014.03.016. Epub 2014 May 24. Mayo Clin Proc. 2014. PMID: 24867394 Review.
84 results